{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:45:36Z","timestamp":1783637136572,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40271-024-00686-7","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T13:01:47Z","timestamp":1712408507000},"page":"457-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perceptions and Acceptance of a Prophylactic Vaccine for Human Immunodeficiency Virus (HIV): A Qualitative Study"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7431","authenticated-orcid":false,"given":"Natalie V. J.","family":"Aldhouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K. H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Al-zubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Oriol Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine C.","family":"El khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"issue":"12","key":"686_CR1","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1002\/eji.201142082","volume":"41","author":"MS Killian","year":"2011","unstructured":"Killian MS, Levy JA. HIV\/AIDS: 30 years of progress and future challenges. Eur J Immunol. 2011;41(12):3401\u201311.","journal-title":"Eur J Immunol"},{"key":"686_CR2","unstructured":"World Health Organization. HIV\/AIDS. Available at: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/hiv-aids. Accessed 22 Mar 2023."},{"key":"686_CR3","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet. Available at: https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 24 Jan 2024."},{"key":"686_CR4","unstructured":"HIV.gov. U.S. Statistics. Available at: https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics. Accessed 26 Oct 2022."},{"issue":"1","key":"686_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2018.304727","volume":"109","author":"JS Becasen","year":"2019","unstructured":"Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006\u20132017. Am J Public Health. 2019;109(1):e1\u20138.","journal-title":"Am J Public Health"},{"key":"686_CR6","unstructured":"Centers for Disease Control and Prevention. HIV and Transgender People: HIV Prevalence. Centers for Disease Control and Prevention; 2022."},{"issue":"5","key":"686_CR7","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/S2352-3018(23)00008-5","volume":"10","author":"AL Wirtz","year":"2023","unstructured":"Wirtz AL, Humes E, Althoff KN, Poteat TC, Radix A, Mayer KH, et al. HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study. Lancet HIV. 2023;10(5):e308\u201319.","journal-title":"Lancet HIV."},{"key":"686_CR8","unstructured":"UNAIDS. Global AIDS Update 2022. Available at: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2022-global-aids-update_en.pdf. Accessed 26 Oct 2022."},{"key":"686_CR9","unstructured":"HIV.gov. Who is at risk for HIV? Available at: https:\/\/www.hiv.gov\/hiv-basics\/overview\/about-hiv-and-aids\/who-is-at-risk-for-hiv. Accessed 28 Oct 2022."},{"key":"686_CR10","unstructured":"HIV.gov. National HIV\/AIDS Strategy (2022-2025). Available at: https:\/\/files.hiv.gov\/s3fs-public\/NHAS-2022-2025.pdf. Accessed 22 Mar 2023."},{"key":"686_CR11","unstructured":"World Health Organization. Pre-exposure prophylaxis (PrEP). Available at: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/prevention\/pre-exposure-prophylaxis. Accessed 22 Mar 2023."},{"key":"686_CR12","unstructured":"Centers for Disease Control and Prevention. PrEP. Available at: https:\/\/www.cdc.gov\/hiv\/basics\/prep\/about-prep.html. Accessed 22 Mar 2023."},{"issue":"22","key":"686_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1021\/acs.biochem.1c00157","volume":"60","author":"KD Engelman","year":"2021","unstructured":"Engelman KD, Engelman AN. Long-acting cabotegravir for HIV\/AIDS prophylaxis. Biochemistry. 2021;60(22):1731\u201340.","journal-title":"Biochemistry"},{"issue":"5","key":"686_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"EO Murchu","year":"2022","unstructured":"Murchu EO, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5): e048478.","journal-title":"BMJ Open"},{"key":"686_CR15","unstructured":"Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2022; and preexposure prophylaxis (PrEP) data reported through December 2021. HIV Surveillance Data Tables 2022;3(2). Available at: https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance-data-tables\/vol-3-no-2\/cdc-hiv-surveillance-tables-vol-3-no-2.pdf. Accessed 22 Mar 2023."},{"issue":"3","key":"686_CR16","volume":"76","author":"M Antonini","year":"2023","unstructured":"Antonini M, Silva IED, Elias HC, Gerin L, Oliveira AC, Reis RK. Barriers to Pre-Exposure Prophylaxis (PrEP) use for HIV: an integrative review. Rev Bras Enferm. 2023;76(3): e20210963.","journal-title":"Rev Bras Enferm"},{"issue":"1","key":"686_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2830","volume":"114","author":"N Parkin","year":"2023","unstructured":"Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, et al. Facilitating next-generation pre-exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the forum HIV prevention trial design project. Clin Pharmacol Ther. 2023;114(1):29\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"686_CR18","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"J-M Molina","year":"2015","unstructured":"Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"686_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jiw077","volume":"214","author":"ML Cottrell","year":"2016","unstructured":"Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55\u201364.","journal-title":"J Infect Dis"},{"key":"686_CR20","unstructured":"Centers for Disease Control and Prevention. On-demand PrEP 2022. Available at: https:\/\/www.cdc.gov\/hiv\/basics\/prep\/on-demand-prep.html."},{"issue":"23","key":"686_CR21","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209\u201320.","journal-title":"N Engl J Med"},{"issue":"11","key":"686_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384(11):1003\u201314.","journal-title":"N Engl J Med"},{"issue":"6623","key":"686_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/science.add6502","volume":"378","author":"DJ Leggat","year":"2022","unstructured":"Leggat DJ, Cohen KW, Willis JR, Fulp WJ, deCamp AC, Kalyuzhniy O, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science. 2022;378(6623): eadd6502.","journal-title":"Science"},{"issue":"697","key":"686_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf3309","volume":"15","author":"KW Cohen","year":"2023","unstructured":"Cohen KW, De Rosa SC, Fulp WJ, deCamp AC, Fiore-Gartland A, Mahoney CR, et al. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Sci Transl Med. 2023;15(697): eadf3309.","journal-title":"Sci Transl Med."},{"issue":"3","key":"686_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/21645515.2016.1247134","volume":"13","author":"MB Gilkey","year":"2017","unstructured":"Gilkey MB, Calo WA, Marciniak MW, Brewer NT. Parents who refuse or delay HPV vaccine: differences in vaccination behavior, beliefs, and clinical communication preferences. Hum Vaccin Immunother. 2017;13(3):680\u20136.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"686_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20226-9","volume":"12","author":"J Murphy","year":"2021","unstructured":"Murphy J, Valli\u00e8res F, Bentall RP, Shevlin M, McBride O, Hartman TK, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021;12(1):1\u201315.","journal-title":"Nat Commun"},{"issue":"1","key":"686_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170550","volume":"12","author":"P Schmid","year":"2017","unstructured":"Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy, 2005\u20132016. PLoS\u00a0One. 2017;12(1): e0170550.","journal-title":"PLoS\u00a0One"},{"key":"686_CR28","doi-asserted-by":"publisher","first-page":"D66","DOI":"10.1016\/j.vaccine.2015.09.035","volume":"33","author":"DA Salmon","year":"2015","unstructured":"Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: causes, consequences, and a call to action. Vaccine. 2015;33:D66\u201371.","journal-title":"Vaccine"},{"issue":"34","key":"686_CR29","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","volume":"33","author":"NE MacDonald","year":"2015","unstructured":"MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161\u20134.","journal-title":"Vaccine"},{"issue":"6","key":"686_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1059840511415861","volume":"27","author":"JA Bartlett","year":"2011","unstructured":"Bartlett JA, Peterson JA. The uptake of human papillomavirus (HPV) vaccine among adolescent females in the United States: a review of the literature. J Sch Nurs. 2011;27(6):434\u201346.","journal-title":"J Sch Nurs"},{"key":"686_CR31","unstructured":"World Health Organization. Ten threats to global health in 2019. Available at: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019. Accessed 26 Oct 2022."},{"issue":"4","key":"686_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280439","volume":"18","author":"JL McCready","year":"2023","unstructured":"McCready JL, Nichol B, Steen M, Unsworth J, Comparcini D, Tomietto M. Understanding the barriers and facilitators of vaccine hesitancy towards the COVID-19 vaccine in healthcare workers and healthcare students worldwide: an umbrella review. PLoS\u00a0One. 2023;18(4): e0280439.","journal-title":"PLoS\u00a0One"},{"issue":"9","key":"686_CR33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"key":"686_CR34","first-page":"45","volume-title":"The health belief model. Health behavior and health education: theory, research, and practice","author":"VL Champion","year":"2008","unstructured":"Champion VL, Skinner CS. The health belief model. Health behavior and health education: theory, research, and practice. 4th ed. San Francisco: Jossey-Bass; 2008. p. 45\u201365.","edition":"4"},{"issue":"Suppl 3","key":"686_CR35","doi-asserted-by":"publisher","first-page":"S250","DOI":"10.1097\/QAI.0000000000000236","volume":"66","author":"MR Kaufman","year":"2014","unstructured":"Kaufman MR, Cornish F, Zimmerman RS, Johnson BT. Health behavior change models for HIV prevention and AIDS care: practical recommendations for a multi-level approach. J Acquir Immune Defic Syndr. 2014;66(Suppl 3):S250\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"686_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"8","key":"686_CR37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding. Value in Health. 2011;14(8):978\u201388.","journal-title":"Value in Health."},{"issue":"3","key":"686_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.926","volume":"304","author":"CJ Cooper","year":"2010","unstructured":"Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR, Force NHVTNV-IST. Vaccine-induced HIV seropositivity\/reactivity in noninfected HIV vaccine recipients. JAMA. 2010;304(3):275\u201383.","journal-title":"JAMA"},{"issue":"6","key":"686_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1177\/0093854807299543","volume":"34","author":"JJ Harman","year":"2007","unstructured":"Harman JJ, Smith VE, Egan LC. The impact of incarceration on intimate relationships. Crim Justice Behav. 2007;34(6):794\u2013815.","journal-title":"Crim Justice Behav"},{"issue":"6","key":"686_CR40","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00404-011-2208-z","volume":"285","author":"A Sotiriadis","year":"2012","unstructured":"Sotiriadis A, Dagklis T, Siamanta V, Chatzigeorgiou K, Agorastos T. Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet. 2012;285(6):1719\u201324.","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"686_CR41","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.healthpol.2020.08.010","volume":"124","author":"Y Brilli","year":"2020","unstructured":"Brilli Y, Lucifora C, Russo A, Tonello M. Influenza vaccination behavior and media reporting of adverse events. Health Policy. 2020;124(12):1403\u201311.","journal-title":"Health Policy"},{"issue":"2","key":"686_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/01.qai.0000179454.93443.60","volume":"41","author":"PA Newman","year":"2006","unstructured":"Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. JAIDS J Acquir Immune Deficiency Syndromes. 2006;41(2):210\u20137.","journal-title":"JAIDS J Acquir Immune Deficiency Syndromes."},{"issue":"11","key":"686_CR43","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/09540121003693522","volume":"22","author":"L Balfour","year":"2010","unstructured":"Balfour L, Corace K, Tasca GA, Tremblay C, Routy J-P, Angel JB. Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173). AIDS Care. 2010;22(11):1403\u20139.","journal-title":"AIDS Care"},{"issue":"1","key":"686_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/09540120600872711","volume":"19","author":"RA Brooks","year":"2007","unstructured":"Brooks RA, Newman PA, Duan N, Ortiz DJ. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care. 2007;19(1):52\u20138.","journal-title":"AIDS Care"},{"issue":"2","key":"686_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09540121.2011.597711","volume":"24","author":"L Dowson","year":"2012","unstructured":"Dowson L, Kober C, Perry N, Fisher M, Richardson D. Why some MSM present late for HIV testing: a qualitative analysis. AIDS Care. 2012;24(2):204\u20139.","journal-title":"AIDS Care"},{"issue":"10","key":"686_CR46","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.vaccine.2014.10.040","volume":"33","author":"Y Voronin","year":"2015","unstructured":"Voronin Y, Zinszner H, Karg C, Brooks K, Coombs R, Hural J, et al. HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. Vaccine. 2015;33(10):1243\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"686_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-020-08844-w","volume":"20","author":"J Hoogink","year":"2020","unstructured":"Hoogink J, Verelst F, Kessels R, Van Hoek AJ, Timen A, Willem L, et al. Preferential differences in vaccination decision-making for oneself or one\u2019s child in The Netherlands: a discrete choice experiment. BMC Public Health. 2020;20(1):1\u201314.","journal-title":"BMC Public Health"},{"issue":"1","key":"686_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/1471-2458-14-537","volume":"14","author":"AM Young","year":"2014","unstructured":"Young AM, DiClemente RJ, Halgin DS, Sterk CE, Havens JR. HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study. BMC Public Health. 2014;14(1):537.","journal-title":"BMC Public Health"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00686-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-024-00686-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00686-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:32:12Z","timestamp":1718897532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-024-00686-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1007\/s40271-024-00686-7","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"29 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Janssen. Clarivate received consulting fees for conducting this study and for preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Natalie V.J. Aldhouse, Tamara Al-zubeidi, Stephanie McKee, and Helen Kitchen are employees and stockholders of Clarivate, a health economic and outcomes research consultancy that consults with various pharmaceutical companies, including Janssen. Eric K.H. Chan and Antoine C. El khoury are employees of Janssen and stockholders of Johnson and Johnson. Val\u00e9rie Oriol Mathieu is a current employee of Janssen Vaccines & Prevention B.V., which is part of the Johnson and Johnson companies, and may own stock or stock options in this company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study protocol was reviewed and approved by the New England Institutional Review Board (NEIRB; 12 March 2020, study number: 1281308), and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All study participants provided freely given, written, informed consent before taking part in the study. Verbal informed consent was also obtained prior to interviews.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available due to confidentiality of the information. However, the corresponding author can be contacted for any data-related questions.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data, Materials and\/or Code Availability"}},{"value":"NVJA, EKHC, VOM, ACE and HK conceptualized and designed this study, and approved the final protocol. NVJA, TAZ, and SM conducted the interviews and analyzed the data. All authors interpreted the data, and read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}